IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups …
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups …
この記事を読む
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. Ou SI et al.J Thorac Oncol. 2022 Apr;17(4):…
この記事を読む
Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia. Fukui M et al.Lung C…
この記事を読む
Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung C…
この記事を読む
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cance…
この記事を読む
Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. Hammerman A et al.N Engl J Med. 2022 Feb 16 Epub ahe…
この記事を読む
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experie…
この記事を読む
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected …
この記事を読む
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a r…
この記事を読む
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Stud…